SEISMIC Shows Safety Of Bioheart’s Myoblast Therapy For Post-MI Patients
This article was originally published in The Gray Sheet
Executive Summary
Investigators are encouraged by results of the unblinded SEISMIC safety trial of Bioheart's MyoCell autologous stem-cell therapy for myocardial infarction, but the benefits of the therapy must still be confirmed in a blinded study